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Abstract
Background: Fibronectin (FN) is a multi-domain molecule involved in many cellular processes, including tissue repair,
embryogenesis, blood clotting, and cell migration/adhesion. The biological activities of FN are mediated by exposed loops
located mainly at the interdomain interfaces that interact with various molecules such as, but not only, integrins. Different
FN isoforms arise from the alternative splicing of the pre-mRNA. In malignancies, the splicing pattern of FN pre-mRNA is
altered; in particular, the FN isoform containing the extra-domain B (ED-B), a complete FN type III repeat constituted by 91
residues, is undetectable in normal adult tissues, but exhibits a much greater expression in fetal and tumor tissues, and is
accumulated around neovasculature during angiogenic processes, thus making ED-B one of the best markers and targets of
angiogenesis. The functions of ED-B are still unclear; however, it has been postulated that the insertion of an extra-domain
such as ED-B modifies the domain-domain interface and may unmask loops that are otherwise cryptic, thus giving FN new
potential activities.
Methodology: We used the mAb C6, which reacts with ED-B containing FN, but not with ED-B-free FN and various
recombinant FN fragments containing mutations, to precisely localize the epitopes recognized by the mAb C6.
Conclusion: We formally demonstrated that the inclusion of the alternatively spliced angiogenesis-associated ED-B leads to
the unmasking of the FNIII 8 B-C loop that is cryptic in FN molecules lacking ED-B. Thus, the mAb C6, in addition to
providing a new reagent for angiogenesis targeting, represents a new tool for the study of the potential biological functions
of the B-C loop of the repeat FNIII 8 that is unmasked during angiogenic processes.
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Introduction
Fibronectins (FNs) are high-molecular-mass adhesive glycopro-
teins (for reviews see [1–3]) present in the extracellular matrix
(ECM) and body fluids, constituted by a dimer composed of two
subunits of about 250 kDa linked at the C-termini by two disulfide
bonds. Each monomer consists of three types of repeating units: 12
FN repeats of type I (about 40 amino acids each), two type II
(about 60 amino acids) and 15–17 type III (about 90 amino acids)
(see Fig. 1A). Fibronectin mediates a wide variety of cellular
interactions and is involved in a number of processes, such as cell
adhesion, the establishment and maintenance of normal cell
morphology, cell migration, growth and differentiation. It interacts
with several other ECM and cell surface proteins, including
collagen, heparin, fibrin, and cell membrane receptors. Finally, FN
can be a ligand for numerous integrins, including the classic FN
receptor alpha5-beta1 on the RGD sequence of repeat III-10 [4].
Fibronectins are the product of a single gene localized on
chromosome 2 [5], but different isoforms arise from the alternative
splicing of the pre-mRNA, a process that for some ECM proteins
is modulated by cytokines and extracellular/intracellular pH [6,7]
in three sites: the type III connecting sequence (IIICS), a complete
type III repeat, extra domain A (ED-A), and a complete type III
repeat, extra domain B (ED-B) (Fig. 1A).
T h el a s to ft h e s ei sac o m p l e t et y p eI I Ih o m o l o g yr e p e a to f9 1
amino acids, in which exon usage or skipping leads toinclusion or
exclusion of these type III repeats. Our laboratory originally
discovered the ED-B through comparative amino acid sequence
analysis of proteolytic fragments of FNs from normal and
transformed human cells, detecting an extra sequence that was
preferentially included in FN from cultured transformed cells [8].
Independently and simultaneously, the ED-B was demonstrated
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confirmed in human and was named EIIIB and EDII,
respectively [9,10]. The sequence of the ED-B is highly
conserved in different species, having 100% homology in all
mammalians thus far studied and 96% homology with a similar
domain in chicken.
The generation of a murine monoclonal antibody (mAb), BC1
[11], selectively specific for FN containging the ED-B (B-FN),
allowed the demonstration by immunohistochemistry that, while
B-FN is undetectable in the tissues of healthy adults (with very rare
exceptions, such as the recurrent physiological processes of tissue
remodeling and angiogenesis occurring in the female reproductive
system), it is, in contrast, abundant in fetal and neoplastic tissues.
This antibody was widely used thereafter by different groups, and
has allowed all of the early extensive immunohistochemical studies
that have clearly established the outstanding presence of B-FN in
different kinds of pathologies, including cancer and all angiogen-
esis-associated pathologies [12,13], that B-FN is an excellent
marker of angiogenesis [13,14] and that the mAb BC1 could be
used to selectively target cancer in vivo [15]. These results
prompted the generation of high-affinity human recombinant
antibodies specific for the ED-B for diagnostic and therapeutic
purposes [16–22].
It has been previously reported that the insertion of the ED-B
between the FN type III repeats 7 and 8 induces a conformational
modification that unmasks a cryptic sequence and hinders others
[23]. In fact, the B-FN specific mAb BC1 reacts with an epitope
localized on FNIII 7 that is accessible only when the ED-B is
included in the FN molecule; on the contrary, another monoclonal
antibody, IST-6, reacts only with FN molecules lacking the ED-B.
We recently described a new high affinity mAb, C6, which reacts
with an epitope localized on FNIII 8 that is hindered when the
ED-B is omitted but unmasked when the ED-B is present within
the FN molecule [24]. We now report on the localization of this
epitope on the B-C loop of FNIII 8.
Results and Discussion
We previously reported on a mAb, C6, which reacts with an
epitope within the FNIII 8 that is hindered when the ED-B is
omitted but available when the ED-B is inserted within the
molecule. However, C6 reacts only with human FN and not with
Figure 1. Reactivity of the mAb C6 with different FN fragments. A. Model of the domain structure of human FN subunit; the three different
types of repeats and the specificity of the mAb C6 for the type III fibronectin repeat 8 are shown; B. Comparison of the amino acid sequence of
human (h8) and mouse (m8) FNIII 8 domains; the differences in mouse FNIII 8 compared to human FNIII 8 are written in white letters on a black
background. We generated four chimerical mutants of the human recombinant fragment FNIII B-8 (mut-1, mut-2, mut-3 and mut-4), substituting
various amino acids of the human FNIII 8 with those of the mouse FNIII 8 sequence. The mouse residues introduced in the human sequence are in
white letters on a black background. The loop B-C is enclosed in a box. The reactivity of each recombinant fragment with the mAb C6 is shown on the
right. C. Reactivity in ELISA of various concentrations of the mAb C6 with human and chimeric FNIII B-8 recombinant fragments: C6 showed reactivity
with human FNIII B-8, mut-1 and mut-3, but not with mut-2 and mut-4.
doi:10.1371/journal.pone.0009145.g001
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sequences containing differences between human and mouse
repeat FNIII 8. We compared the sequences of human and mouse
FNIII 8 and, as is shown in Fig. 1B, they differ in only four amino
acids, specifically at positions 29, 33, 70 and 83.
We generated chimerical mutants of human FNIII B-8
fragment substituting the human amino acids with the mouse
amino acids and then tested the reactivity with the human specific
antibody C6 by ELISA and immunoblot. ED-B is identical in
mouse and human so the mutations were introduced only in the
FNIII 8.
We first generated two mutants by substituting Val70RLeu and
Thr83RIle for mut-1 and Asp29RGlu and Phe33RLeu for mut-
2. The recombinant proteins obtained from these two mutated
cDNA showed that, in ELISA as well in immunoblot experiments,
while mut-2 did not react with C6, mut-1 did not lose any
immunoreactivity, thereby indicating that the epitope was
localized among residues 29–33 of FNIII 8. Thus, we produced
two new mutants, mut-3 and mut-4 with only one substitution
each, Phe33RLeu and Asp29RGlu, respectively. The purified
recombinant proteins obtained from these mutated cDNAs
showed that mut-3 reacted, in ELISA experiments, with the C6
as well as the wild-type, while mut-4 completely lost its
immunoreactivity (Fig. 1C). In immunoblot expriments, howewer,
the reaction with C6 of mut-3 was weaker with respect to the
completely human fragment. These results demonstrate that the
epitope recognized by the monoclonal antibody C6 encompasses
the Asp29 residue and the Phe33 may play a role in stabilizing it.
This demonstrates that the epitope recognized by C6 is localized
within the FNIII 8 loop B-C of which the Asp29 is definitively a
part, and that this loop is hindered at the interface FNIII 7–8 but
exposed at the interface FNIII B-8 (Fig. 2B).
Our conclusions concur with previously reported structural
studies. The crystal structure of a human FN fragment of four type
III repeats has shown a rod-like molecule with a highly variable
relationship between the pairs of adjacent domains (type III
repeats) [25]. The relative orientation of adjacent pairs of domains
is regulated by interaction at the interdomain interfaces, which are
largely composed of the loops located near the N and C termini of
each domain [25,26]. The type III homology repeat domains,
independently of the degree of sequence homology, have highly
conserved global folds and differ only in the loop regions, loops
Figure 2. Westernblot of FN fragments using mAb C6 and structural comparison of interfaces FNIII 7/FNIII 8 and ED-B/FNIII 8. A.
Coomassie blue staining of the human FN wild-type and mutated recombinant fragments FNIII 7-B, FNIII 7-B-8-9, FNIII 7-8-9, FNIII 7-8, mut-2, mut-1,
FNIII B-8, mut-3 and mut-4 (left panel); reactivity in immunoblotting of the mAb C6 with the generated FN recombinant fragments: C6 reacted with
FNIII 7-B-8-9, FNIII B-8, mut-1 and mut-3, but was negative with FNIII 7-B, FNIII 7-8-9, FNIII 7-8, mut-2 and mut-4 (right panel). B. Structural comparison
of the interface between the ED-B/FNIII 8 and between the FNIII 7/FNIII 8 domains by superimposition of structures of the ED-B with FNIII 7. The FNIII
7 and ED-B loops A-B and the FNIII 8 loop B-C are indicated (adapted with permission from Fattorusso, R., et al., license number 2247580530397,
dated Aug 14, 2009).
doi:10.1371/journal.pone.0009145.g002
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regard to the FNIII 7–8 interface, reports have described that the
inter-domain relationship is rigid and that the B-C loop of FNIII 8
is buried [25,27,28]. In fact, the interface FNIII 7–8 possesses a
unique feature, namely an insertion of two amino acids in the A-B
loop of FNIII 7 that influences the orientation of FNIII 7 and 8 by
increasing the buried interface area [25] and that very likely
accounts for the masking of the B-C loop of FNIII 8 (Fig. 2B). The
insertion of the ED-B between FNIII 7 and FNIII 8 dramatically
modified the inter-domain interfaces and interactions, with
consequent conformational modifications including different
domain orientation, the generation of new potential functional
surfaces and the exposure of otherwise cryptic sequences [25]. In
fact, it has been reported on differences in the location and
conformation of the A-B, C-C9 and E-F loops in the ED-B
compared to those of FNIII 7 [27]. These differences lead to the
distinct buried inter-domain surface in FNIII 7–8 with respect to
that of FNII B-8: the same authors show that the inter-domain
linker between ED-B and FN8 buries a 416 A ˚ 2 surface, while the
buried surface between FN7 and FN8 is 587 A ˚ 2, with an opening
up of the surface area that exceeds 170 A ˚ 2 as a consequence of the
inclusion of the ED-B [25,27]. Our results are in line with these
observations and experimentally demonstrate that the B-C loop of
FN 8 is buried at the interface FNIII 7–8, while it is unmasked at
the B-8 interface. Thus, the mAb C6, in addition to providing a
new reagent for angiogenesis targeting, represents a new tool for
the study of the biological activities of FN that are modified by the
insertion of the angiogenesis-associated ED-B and, in particular,
the potential biological functions of the B-C loop of the repeat
FNIII 8.
Materials and Methods
Preparation of Wild-Type and Mutated Human FN
Recombinant Fragments Containing the Type III Repeats
ED-B (B) and 8, ELISA and Immunoblotting Assays
The cDNA encoding for human FNIII B-8 recombinant
fragment, cloned into the bacterial expression vector pProEX-1
(Life Technologies, Gaithersburg, Maryland), was previously
described [16]. The cDNA sequence of mut-1 was obtained by
PCR from the cDNA of human FNIII B-8, using the primer
forward TI-147 (59-ctcgaattcaagaggtgccccaactcact-39) and the
primer reverse TI-148 (59-ctcggatcctgttttctgtcttcctctaagaggtatgctct-
catgttgttcgtagacactggagacactcactagatattc-39), including the EcoRI
and BamHI resctriction sites, respectively. The obtained sequence
was EcoRI/BamHI digested and inserted into EcoRI/BamHI
digested pProEX-1. The cDNAs of mut-2, mut-3 and mut-4,
cloned into pProEX-1, were generated by site-directed mutagen-
esis from human FNIII B-8 cDNA and provided by Genscript
Corporation (Piscataway, NJ, USA).
All PCR reactions were performed with high fidelity PWO
DNA Polymerase (Roche Diagnostic, Basel, Switzerland) following
the manufacturer’s instructions. The restriction enzymes were
from Roche Diagnostics.
The DNA constructs were used to transform DH5a competent
bacteria cells and the recombinant wild-type and mutated FNIII
B-8 fragments were purified from the bacterial lysate on Ni-NTA
columns (Quiagen, Hilden, Germany) using the His6 tag
appended at the N-terminus of the FN fragments, according to
the manufacturer’s instructions. The purified proteins were
analyzed by SDS-PAGE under reducing conditions as previously
described [21].
The recombinant fragments FNIII 7-B, FNIII 7-8-9, FNIII 7-B-
8-9 and FNIII 7–8 were previously described [16].
The reactivity of the monoclonal antibody C6 [24] with
recombinant wild-type and mutated FN fragments was assessed
by ELISA and immunoblotting assays as previously described
[24].
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